Vifor Pharma AG Logo

Vifor Pharma AG

A global leader in specialty pharmaceuticals for iron deficiency and nephrology.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CSL Vifor is a global specialty pharmaceuticals company and a leader in iron deficiency and nephrology therapies. As a pioneer in iron-based treatments, the company develops, manufactures, and markets innovative products for iron deficiency anemia and related conditions in areas including heart failure, gastroenterology, and women's health. In partnership with its joint company, Vifor Fresenius Medical Care Renal Pharma, CSL Vifor is expanding its presence in nephrology, committed to launching therapies that address the full spectrum of kidney disease. The company specializes in strategic global partnering, in-licensing, and marketing pharmaceutical products to serve patients with unmet medical needs in over 100 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Company Country Ticker View
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan 4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark STENO
ST PHARM CO., LTD. Logo
A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.
South Korea 237690
Sugentech, Inc. Logo
Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.
South Korea 253840
SUHEUNG CO.,LTD. Logo
Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.
South Korea 008490
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan 4506
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea 067370
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan 4582

Talk to a Data Expert

Have a question? We'll get back to you promptly.